CoChat

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme

Niswender, K., Pi‐Sunyer, X., Buse, J., Jensen, K. H., Toft, A. D., Russell‐Jones, D., Zinman, B. · 2013 · Diabetes, Obesity and Metabolism
Cited by 100

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Aim: We investigated the relationship between weight change and related factors in subjects with type 2 diabetes mellitus ( T2DM ) treated with liraglutide versus comparator diabetes therapies. Methods: Twenty‐six‐week data from seven phase 3, randomized trials in the liraglutide T2DM development programme were analysed by trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and placebo. Outcome measures included proportions of subjects in various weight change categories and their percentage weight change from baseline; impact of body mass index ( BMI ) and gastrointestinal ( GI ) adverse events ( AEs ) on weight change and correlation of weight change with change in glycosylated haemoglobin ( HbA1c ). Results: A number of subjects experienced >5% weight loss during the trials (24.4% liraglutide 1.8 mg and 17.7% liraglutide 1.2 mg; 17.7% exenatide, 10.0% sitagliptin, 3.6−7.0% sulphonylurea, 2.6% thiazolidinedione and 2.6% glargine; 9.9% placebo). More weight loss was seen with liraglutide 1.2 and 1.8 mg than with active comparators except exenatide. Across trials, higher initial BMI was associated with slightly greater weight loss with liraglutide. Mean weight loss increased slightly the longer GI AEs persisted. Although HbA1c reduction was slightly larger in higher weight loss categories across treatments (including placebo), sample sizes were small and no clear correlation could be determined. Liraglutide‐treated subjects experienced additional HbA1c reduction beyond that which appeared weight induced; thus, not all HbA1c ‐lowering effect appears weight mediated. Conclusions: The majority of liraglutide‐treated T2DM subjects experienced weight loss in this analysis. Weight loss was greater and occurred more in glucagon‐like peptide‐1 receptor agonist‐treated subjects than in active comparator‐treated subjects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2012.01673.x

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 100

Metadata

Authors
Niswender, K., Pi‐Sunyer, X., Buse, J., Jensen, K. H., Toft, A. D., Russell‐Jones, D., & Zinman, B.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-09-09
Volume
15
Issue
1
Pages
42-54
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2033185429
Cited by
100
References
19
FWCI
12.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01673.x
The paper
Niswender, K., Pi‐Sunyer, X., Buse, J., Jensen, K. H., Toft, A. D., Russell‐Jones, D., & Zinman, B. (2013). Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01673.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.